Merck & Co., Inc. (MRK)
Stock Price Chart
Key Info
| Market Cap | 198.85B |
| Revenue (ttm) | 48.08B |
| Net Income (ttm) | 10.15B |
| Shares Out | 2.52B |
| EPS (ttm) | 3.95 |
| PE Ratio | 19.94 |
| Forward PE | 14.47 |
| Dividend | $2.44 |
| Dividend Yield | 3.10% |
Stock Quote
| Trading Day | Jul 2, 2020 |
| Last Price | $78.78 |
| Previous Close | $78.12 |
| Change ($) | 0.66 |
| Change (%) | 0.84% |
| Day's Open | 78.57 |
| Day's Range | 78.22 - 79.31 |
| Day's Volume | 6,515,116 |
| 52-Week Range | 65.25 - 92.64 |
More Stats
| Market Cap | 198.85B |
| Enterprise Value | 219.41B |
| Earnings Date (est) | Jul 31, 2020 |
| Ex-Dividend Date | Jun 12, 2020 |
| Shares Outstanding | 2.52B |
| Float | 2.52B |
| EPS (basic) | 3.98 |
| EPS (diluted) | 3.95 |
| FCF / Share | 3.53 |
| Dividend | $2.44 |
| Dividend Yield | 3.10% |
| Earnings Yield | 5.01% |
| FCF Yield | 4.50% |
| Payout Ratio | 58.30% |
| Shares Short | 15.81M |
| Short Ratio | 1.49 |
| Short % of Float | 0.63% |
| Beta | 0.50 |
| PE Ratio | 19.94 |
| Forward PE | 14.47 |
| P/FCF Ratio | 22.23 |
| PS Ratio | 4.14 |
| PB Ratio | 7.39 |
| Revenue | 48.08B |
| Operating Income | 12.26B |
| Net Income | 10.15B |
| Free Cash Flow | 8.95B |
| Net Cash | -20.57B |
| Net Cash / Share | -8.15 |
| Gross Margin | 70.06% |
| Operating Margin | 25.49% |
| Profit Margin | 21.10% |
| FCF Margin | 18.61% |
| ROA | 11.76% |
| ROE | 37.55% |
| ROIC | 25.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46,840 | 42,294 | 40,122 | 39,807 | 39,498 | 42,237 | 44,033 | 47,267 | 48,047 | 45,987 |
| Revenue Growth | 10.75% | 5.41% | 0.79% | 0.78% | -6.48% | -4.08% | -6.84% | -1.62% | 4.48% | - |
| Gross Profit | 32,728 | 28,785 | 27,210 | 25,777 | 24,564 | 25,469 | 27,079 | 30,821 | 31,176 | 27,591 |
| Operating Income | 11,603 | 8,299 | 6,021 | 4,848 | 6,928 | 5,670 | 5,956 | 9,213 | 7,670 | 2,370 |
| Net Income | 9,843 | 6,220 | 2,394 | 3,920 | 4,442 | 11,920 | 4,404 | 6,168 | 6,272 | 861 |
| Shares Outstanding | 2,546 | 2,600 | 2,724 | 2,757 | 2,794 | 2,851 | 2,922 | 3,040 | 3,048 | 3,081 |
| Earnings Per Share | 3.81 | 2.32 | 0.87 | 1.41 | 1.56 | 4.07 | 1.47 | 2.00 | 2.02 | 0.28 |
| EPS Growth | 64.22% | 166.67% | -38.3% | -9.62% | -61.67% | 176.87% | -26.5% | -0.99% | 621.43% | - |
| Dividend Per Share | 2.26 | 1.99 | 1.89 | 1.85 | 1.81 | 1.77 | 1.73 | 1.69 | 1.56 | 1.52 |
| Dividend Growth | 13.57% | 5.29% | 2.16% | 2.21% | 2.26% | 2.31% | 2.37% | 8.33% | 2.63% | - |
| Operating Cash Flow | 13,440 | 10,922 | 6,451 | 10,376 | 12,538 | 7,989 | 11,654 | 10,022 | 12,383 | 10,822 |
| Capital Expenditures | -3,473 | -2,615 | -1,888 | -1,614 | -1,283 | -1,317 | -1,548 | -1,954 | -1,723 | -1,678 |
| Free Cash Flow | 9,967 | 8,307 | 4,563 | 8,762 | 11,255 | 6,672 | 10,106 | 8,068 | 10,660 | 9,144 |
| Cash & Equivalents | 10,450 | 8,864 | 8,498 | 14,341 | 13,427 | 15,719 | 17,486 | 16,141 | 14,972 | 12,201 |
| Total Debt | 26,346 | 25,114 | 24,410 | 24,842 | 26,412 | 21,403 | 25,060 | 20,569 | 17,515 | 17,882 |
| Net Cash / Debt | -15,896 | -16,250 | -15,912 | -10,501 | -12,985 | -5,684 | -7,574 | -4,428 | -2,543 | -5,681 |
| Assets | 84,397 | 82,637 | 87,872 | 95,377 | 101,677 | 98,167 | 105,645 | 106,132 | 105,128 | 105,781 |
| Liabilities | 58,396 | 55,755 | 53,303 | 55,069 | 56,910 | 49,376 | 53,319 | 50,669 | 48,185 | 48,976 |
| Book Value | 25,907 | 26,701 | 34,336 | 40,088 | 44,676 | 48,647 | 49,765 | 53,020 | 54,517 | 54,376 |
Company Profile
Company Details
| Full Name | Merck & Co., Inc. |
| Country | United States |
| Employees | 71,000 |
| CEO | Kenneth C. Frazier |
Stock Information
| Ticker Symbol | MRK |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: MRK |
Description
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through Pharmaceutical and Animal Health segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products; and dog, cat, and horse vaccines. The company serves drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; PeptiDream Inc.; Shanghai Junshi Biosciences Co., Ltd.; Targovax ASA; and Linnaeus Therapeutics, Inc. It also has strategic research collaboration and license agreement with Yumanity Therapeutics. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.